Pentixapharm Reports Third Quarter and Nine Months 2026 Results, Confirms Revised 2026 Outlook

Pentixapharm Holding AG

/ Key word(s): Quarterly / Interim Statement

Pentixapharm Reports Third Quarter and Nine Months 2026 Results, Confirms Revised 2026 Outlook

12.11.2026 / 08:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


Pentixapharm Reports Third Quarter and Nine Months 2026 Results, Confirms Revised 2026 Outlook

Berlin, Germany, November 12, 2026 – Pentixapharm Holding AG (Frankfurt Prime Standard: PTP), a clinical-stage biotechnology company developing radiopharmaceutical diagnostics and therapeutics, today reported financial results for the third quarter and nine months ended September 30, 2026, and provided an update on its development portfolio and strategic priorities. Following the €20.4 million gross capital raise completed during the quarter, the Company continues to expect its available financial resources to fund operations into 2028. Pentixapharm confirmed the revised guidance announced on October 19, 2026, for a full-year net loss of approximately €13 million. Previously, a net loss of approximately €21.6 million had been expected.

“The financing completed in the third quarter allows us to plan the next stage of development from a stronger financial position,” said Dr. Dirk Pleimes, Chief Executive Officer of Pentixapharm. “Our task is to direct those resources toward the clinical evidence needed to establish the value of our programs. PANDA is our principal near-term priority, while our oncology portfolio offers further opportunities to apply CXCR4-targeted imaging and therapy. As we prepare for 2027, we are balancing investment in these programs with the partnerships needed to support their development and future commercialization.”

Third Quarter and Nine Months 2026 Financial Highlights

  • Cash position: €21.9 million in cash and cash equivalents as of September 30, 2026 (December 31, 2025: €4.6 million).
  • Capital increase: rights offering and significantly oversubscribed private placement completed in July 2026; all 11,020,212 new shares placed at €1.85 per share for gross proceeds of approximately €20.4 million.
  • Convertible bond: €5.0 million drawn; further €13.5 million can be drawn.
  • Cash runway: available financial resources expected to fund operations into 2028.
  • Net loss: €7.7 million for the first nine months (restated prior-year period: €10.4 million) and €2.5 million for the third quarter (Q3 2025: €3.5 million).
  • Operating cash flow: negative €7.3 million for the first nine months (restated prior-year period: negative €15.6 million).

Revenue, EBITDA and earnings per share are reported in the interim report.

Financial Reporting Review

In October 2026, BaFin concluded its review of Pentixapharm’s 2024 consolidated financial statements with findings of errors. BaFin found that intangible assets as of December 31, 2024 were overstated by €34.7 million and the capital reserve by €21.6 million. The intangible asset findings comprise €21.6 million from purchase price allocation carrying amounts at the former shareholder level and €13.1 million of PentixaFor development expenditure incurred in 2021–2024 that did not meet the capitalization criteria in BaFin’s view. The Management Board decided not to appeal and assessed the findings as having no material effect on operations, liquidity or business prospects.

The accounting adjustments arising from BaFin’s findings have been implemented internally. Prior periods are restated under IAS 8, with consequential effects reflected in the 2026 accounts, including the elimination of scheduled amortization of the affected intangible assets. The correction is non-cash. The interim report is unaudited.

Revised Full Year 2026 Financial Guidance Confirmed

Pentixapharm confirms the revised full-year guidance announced on October 19, 2026, after the end of the reporting period. The Company expects a net loss of approximately €13 million for 2026, a decrease of approximately €8.6 million from the previous forecast of €21.6 million.

The revision reflects cost deferrals and reductions as well as changes in amortization. Approximately €3 million relates to PANDA study expenses, part of which shift into 2027 following firmed-up service-provider agreements and the adjusted study timeline. Approximately €2 million relates to other effects, including lower personnel costs and data-acquisition expenditure deferred beyond year-end 2026. A further non-cash effect of approximately €3.7 million for full-year 2026 primarily reflects the elimination of scheduled amortization of intangible assets following BaFin’s October findings.

The reduction in cash expenses lowers expected cash outflows in 2026. The Company’s assessment that available financial resources will fund operations into 2028 remains unchanged. The revised outlook continues to exclude potential revenues from partnership and out-licensing agreements.

Business Highlights

PANDA Remains the Principal Clinical Development Priority

Following the U.S. study preparation update issued on November 4, Pentixapharm’s focus is on bringing participating PANDA centers into operation ahead of first-patient enrollment, which remains expected in Q1 2027. The Company currently expects no material impact on the subsequent study timeline. PANDA is the principal near-term focus of clinical investment; the revised phasing of expenditure is reflected in the full-year financial outlook.

“With Fast Track designation, a final protocol on which the FDA raised no concerns and approval by the central institutional review board in October, the regulatory groundwork for PANDA in the United States is in place,” said Erik Merten, Chief Technology Officer and Chief Operating Officer of Pentixapharm. “After qualification visits, we have selected more than ten centers for final contract negotiations. Our focus now is to activate these sites and enroll the first patient in the first quarter of 2027.”

The registrational study will evaluate [⁶⁸Ga]Ga-PentixaFor PET/CT in approximately 325 adults with confirmed primary aldosteronism. It is designed to establish whether the imaging approach can support treatment selection by identifying patients with unilateral disease who may benefit from surgery. The study addresses subtyping after primary aldosteronism has been confirmed, to help guide the choice between surgical and medical treatment.

International Evidence Supports the PANDA Rationale

After the reporting period, Pentixapharm highlighted evidence presented at EANM 2026 in Vienna supporting the use of PentixaFor PET in primary aldosteronism. Findings from the French PENTALON study added to investigator-led European and Australian research, with further datasets from China generated independently of Pentixapharm. The evidence supports evaluation of the approach in PANDA; it does not replace the registrational study required for the Company’s product.

Oncology Portfolio and Partnership Strategy

The planned Phase I/II PENTHERA program combines PentixaFor imaging with [⁹⁰Y]Y-PentixaTher for targeted bone marrow conditioning before stem cell transplantation in acute myeloid leukemia and multiple myeloma. The FDA cleared the two supporting INDs in February 2026. Initiation remains subject to portfolio priorities, resources and potential strategic partnerships. In October 2026, after the reporting period, the Management Board decided to terminate the Phase I/II PTT101 study in central nervous system lymphoma to focus resources on acute myeloid leukemia and multiple myeloma. The decision was not based on safety or efficacy concerns. Experience with [⁹⁰Y]Y-PentixaTher from PTT101 feeds directly into the PENTHERA program.

The investigator-initiated PENTILULA study evaluates [¹⁷⁷Lu]Lu-PentixaTher in relapsed or refractory acute myeloid or acute lymphoblastic leukemia. Recruitment and treatment have been completed, including treatment at 12.5 GBq, and one-year follow-up is underway. CHU Nantes expects to publish interim results still in 2026. Recruitment is also complete in PENTIMYELO, which evaluates [⁶⁸Ga]Ga-PentixaFor imaging at diagnosis and for treatment assessment in multiple myeloma, including comparison with standard [¹⁸F]FDG PET. Patients remain in follow-up for up to five years. Both investigator-initiated studies are sponsored by CHU Nantes. The Company’s preclinical portfolio also includes the glycan-dependent CD24 antibody platform, including GT-008.

Strategic partnerships and out-licensing remain important to the development of both diagnostic and therapeutic programs. In the United States, Pentixapharm is seeking partners for future commercialization while focusing its own activities on development and the work required to support a potential marketing application.

Operational Progress and Strategic Outlook

Looking toward 2027, Pentixapharm’s priorities are execution of its lead clinical program, continued assessment of the development opportunities across its oncology portfolio and advancement of its partnering strategy. Investment decisions will reflect clinical priorities, available resources and opportunities to share development and commercialization responsibilities with partners.

Management will discuss the nine-month financial performance, capital allocation and development priorities in today’s results webcast, including the remaining steps toward PANDA enrollment.

Investor Webcast

Pentixapharm will host a webcast today, November 12, 2026, at 15:00 CET / 14:00 GMT / 09:00 EST. Management will discuss the financial results and business developments, followed by a question-and-answer session for shareholders, investors, analysts and media.

Webcast registration: https://www.nuways-ag.com/events/pentixapharm-earnings-call-2026-11-12 The presentation will be available subsequently on the Company’s website under Investors.

 

Availability of Financial Statements

The interim report for the third quarter and first nine months of 2026 is available on the Company’s Investor Relations website at www.pentixapharm.com/investors/reports .

About Pentixapharm

Pentixapharm Holding AG (Frankfurt Prime Standard: PTP) is a clinical-stage biotechnology company headquartered in Berlin developing innovative nuclear medicine approaches to help physicians detect, characterize, and treat serious diseases with greater precision. The Company’s compounds are designed to deliver medical radioisotopes specifically to defined biological targets – either for high-resolution molecular imaging or for targeted radioligand therapy.

Pentixapharm’s pipeline is built on CXCR4 targeting, a receptor with strong scientific validation across multiple disease areas, and encompasses diagnostic and therapeutic programs in endocrine, cardiovascular, and oncological indications. The lead program, [⁶⁸Ga]Ga-PentixaFor, is being advanced into the registrational Phase 3 PANDA study for non-invasive subtyping of primary aldosteronism. The planned PENTHERA Phase I/II program is intended to advance the CXCR4-directed theranostic platform in oncology. Complementing the CXCR4 platform, Pentixapharm is also developing a next-generation antibody platform targeting CD24, an emerging immune checkpoint in difficult-to-treat cancers.

Forward-Looking Statements

This press release contains forward-looking statements based on the current beliefs, expectations and assumptions of the management of Pentixapharm Holding AG. These statements relate to future events, prospects or financial performance and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially, positively or negatively, from those expressed or implied by such forward-looking statements. Such factors include, among others, changes in general economic and business conditions, competitive pressures, the introduction of competing products, limited market acceptance of new products, services or technologies, regulatory developments and changes in business strategy. Pentixapharm Holding AG does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements are made only as of the date of this press release. All information provided in this press release is supplied without any warranty or guarantee as to its accuracy, completeness or timeliness. To the extent permitted by law, Pentixapharm Holding AG assumes no liability in connection with this press release.

Pentixapharm Investor and Media Contact

Investor Relations
Robert-Rössle-Straße 10
13125 Berlin, Germany
E-mail: ir@pentixapharm.com
Website: www.pentixapharm.com


12.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Pentixapharm Holding AG
Robert-Rössle-Straße 10
13125 Berlin
Germany
E-mail: info@pentixapharm.com
Internet: https://www.pentixapharm.com/
ISIN: DE000A40AEG0, DE000A383RV0
WKN: A40AEG
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
LEI Code: 3912005VBOVXNDXEQZ36
EQS News ID: 2433394

 
End of News EQS News Service

2433394  12.11.2026 CET/CEST

Eckert & Ziegler: Adjusted EBIT +25% in the Third Quarter. 2026 Forecast Confirmed

Eckert & Ziegler SE

/ Key word(s): 9 Month figures

Eckert & Ziegler: Adjusted EBIT +25% in the Third Quarter. 2026 Forecast Confirmed

12.11.2026 / 07:45 CET/CEST

The issuer is solely responsible for the content of this announcement.


3rd quarter of 2026:

  • Sales of €79.6 million (previous year: €75.3 million)
  • EBIT before special items of €19.3 million (previous year: €15.4 million)
  • Net income of €13.1 million (previous year: €8.5 million)

First 9 months of 2026:

  • Sales of €229.0 million (previous year: €224.1 million)
  • EBIT before special items of €52.6 million (previous year: €50.8 million)
  • Net income of €35.4 million (previous year: €29.9 million)

Forecast for 2026:

  • Sales of around €320 million (confirmed)
  • EBIT before special items of around €80 million (confirmed)

Berlin, 12 November 2026. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased sales by 2% to €229.0 million in the first nine months of 2026 compared to the same period last year. EBIT before special items (adjusted EBIT) rose by just under 4% to €52.6 million. Net income increased by 19% to €35.4 million, or €0.57 per share.

Sales in the prior year included €5.0 million in license revenue, which was not matched by license revenue in the first nine months of 2026. Excluding this licensing effect, consolidated sales grew by €9.8 million, or 4% (previous year, excluding licensing effect: €219.1 million), and the Group’s adjusted EBIT increased by €6.6 million, or 14% (previous year, excluding licensing effect: €46.0 million). The Group’s operating profitability has thus improved significantly. License revenue is expected in the fourth quarter.

In the Medical segment, external sales in the first nine months of the year totaled €121.4 million, up approximately €1.8 million, or 1%, from the prior-year level. Adjusted for the licensing effect, external sales in the Medical segment rose by €6.8 million, or 6% (previous year, excluding licensing effect: €114.7 million). The pharmaceutical radioisotope business remains the most important revenue generator and the key growth driver. In addition to the continued growth in the generator business, developments in lutetium-177 revenue and in the Contract Development & Manufacturing (CDMO) business are particularly noteworthy. Adjusted EBIT for the Medical segment was €36.2 million, up €5.1 million (16%) from the adjusted EBIT in the prior-year period. Excluding the earnings contribution from the licensing business in the prior year (€4.8 million), the increase amounts to €9.9 million, or 38% (previous year, excluding licensing effect: €26.3 million).

The Isotope Products segment generated external sales of €107.5 million, up 3% from the prior year. Following a weaker start to the year, the momentum gained in March continued into the third quarter; external sales in the third quarter were approximately 8% higher than in the same quarter of the prior year. This development was driven by strong business with medical radiation sources as well as project business. Adjusted EBIT in the Isotope Products segment declined by approximately €2.2 million, or 11%, to €17.9 million. In the third quarter, adjusted EBIT of €8.6 million exceeded the prior-year figure (€7.8 million), with the gross margin improving to 47% (previous year: 45%).

For the fourth quarter, the company expects license revenues and positive business performance due to continued strong demand for radiopharmaceutical products, enabling it to achieve the financial targets set for fiscal year 2026. The Executive Board confirms its forecast for fiscal year 2026, published on 26 March 2026, with sales of approximately €320 million and adjusted EBIT of approximately €80 million.

The complete quarterly report can be viewed here: https://www.ezag.com/Q32026en

About Eckert & Ziegler.
Eckert & Ziegler SE, with more than 1,100 employees, is THE leading independent radioisotope supplier and a specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de; www.ezag.com


12.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Eckert & Ziegler SE
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-0
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX, TecDax,
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX
LEI Code: 391200EUDABLUKXCKG48
EQS News ID: 2432992

 
End of News EQS News Service

2432992  12.11.2026 CET/CEST

Fresenius completes sale of 13.4 million Fresenius Medical Care shares at €39.00 per share, raising approximately €524 million

Fresenius SE & Co. KGaA

/ Key word(s): Investment

Fresenius completes sale of 13.4 million Fresenius Medical Care shares at €39.00 per share, raising approximately €524 million (news with additional features)

12.11.2026 / 07:45 CET/CEST

The issuer is solely responsible for the content of this announcement.


  • Fresenius has sold 13.4 million shares in Fresenius Medical Care AG at a price of €39.00 per share, generating gross proceeds of approximately €524 million
  • Fresenius’s financial investment in Fresenius Medical Care reduces from approximately 25 per cent1 to approximately 20 per cent1 of issued share capital
  • Since the deconsolidation of Fresenius Medical Care, Fresenius has reduced the financial investment from approximately 32 per cent1 at deconsolidation to approximately 20 per cent1, for cumulative gross proceeds of approximately €2.3 billion
  • Proceeds will be used consistently with the stated capital allocation priorities set out under #FutureFresenius

Fresenius SE & Co. KGaA (XETR: FRE; OTCM: FSNUY) today completed the sale of 13.4 million shares in Fresenius Medical Care AG (XETR: FME; NYSE: FMS), announced on 11 November 2026, at a placing price of €39.00 per share. The placing generates gross proceeds of approximately €524 million and reduces Fresenius’s financial investment in Fresenius Medical Care to approximately 20 per cent1 of issued share capital. Settlement is expected on 16 November 2026.

“The successful transaction is another step in our disciplined management of our Fresenius Medical Care investment and reflects the strategic direction we have set out with #FutureFresenius. We are freeing up capital to invest in our growth platforms and pursue our strategic priorities in the REJUVENATE phase,” said Sara Hennicken, CFO of Fresenius.

The net proceeds will be available for investment in Fresenius’ growth platforms, consistent with the stated capital allocation priorities set out under #FutureFresenius.
 

●●●

Transaction Details

  • The placing was conducted as an accelerated bookbuild offering to institutional investors, with BNP Paribas, BofA Securities Europe SA, Deutsche Bank Aktiengesellschaft and J.P. Morgan SE acting as Joint Bookrunners.
  • Fresenius remains subject to a lock-up on its remaining shares of 90 days.
  • The anticipated book gain in the low to mid double-digit million euro range will be reflected in Fresenius Group’s Q4 2026 results, classified as special item.

 

●●●
Footnotes
1 Prior to any future exchange of bonds into Fresenius Medical Care shares and prior to any share cancellation under the current Fresenius Medical Care share buyback program 

Press Contact:
Steffi Kim
Group Communications
Fresenius SE & Co. KGaA 
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
M +49 175 3284 722
steffi.kim@fresenius.com

Fresenius (XETR: FRE, OTCM: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, medical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450 million people each year. Fresenius Helios is Europe’s largest private hospital operator, treating around 27 million patients annually.

With more than 178,000 employees and operating in more than 60 countries, Fresenius generated €22.6 billion in revenue in 2025.

For more information, visit www.fresenius.com and follow Fresenius on LinkedIn.

Fresenius Medical Care AG is an independent, separately listed company (XETR: FME; NYSE: FMS), in which Fresenius SE & Co. KGaA holds a financial investment of approximately 25 per cent1; Fresenius Medical Care’s results are not consolidated in the Fresenius Group’s revenue and earnings.

Forward-Looking Statements
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Correspondence Address
 

Fresenius SE & Co. KGaA
 
Fresenius Management SE
Registered Office
Bad Homburg, Germany
 
Registered Office
Bad Homburg, Germany
 
Commercial Register
Amtsgericht Bad Homburg, HRB 11852
 
Commercial Register
Amtsgericht Bad Homburg, HRB 11673
 
Chairman of the Supervisory Board
Wolfgang Kirsch
Management Board
Michael Sen (Chairman), Sara Hennicken,
Dr. Marc-Alexander Mahl, Dr. Michael Moser,
Dr. Christian Pawlu 

Chairman of the Supervisory Board
Wolfgang Kirsch

Securities Information
Fresenius SE & Co. KGaA is listed on the Frankfurt Stock Exchange and is a member of the DAX 40 index. The shares are traded on Xetra, the electronic trading venue of Deutsche Börse, under the ticker FRE.
ISIN: DE000FRE5EN2 ● WKN: FRE5EN

American Depository Receipts
Fresenius SE & Co. KGaA maintains a sponsored Level I American Depositary Receipt programme, traded over the counter in the United States on the OTC Markets platform under the ticker FSNUY, at a ratio of four American Depositary Receipts to one ordinary share. Depositary bank: J.P. Morgan Chase Bank N.A.
ISIN: US35804M1053 ● CUSIP: 35804M105

Contacts
For Media contacts, click here, and to contact Investor Relations, click here.

IMPORTANT NOTICE

This announcement is not a prospectus and does not contain or constitute an offer of securities for sale in or into any jurisdiction, including the United States, Canada, Australia, Japan, South Africa or any jurisdiction in which offers or sales of the securities would be prohibited by applicable law. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction.

This announcement is not an offer to sell, or solicitation of an offer to buy, any securities in the United States. The securities described herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will be no public offering of the securities described herein in the United States or anywhere else.

In member states of the European Economic Area (“EEA”) and the United Kingdom, this announcement is directed exclusively at persons who are “qualified investors” within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (“Prospectus Regulation”) or the Public Offers and Admissions to Trading Regulations 2024 (“POATRs”) (“Qualified Investors”).

In addition, in the UK, this announcement is only being distributed to and is only directed at (i) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), (ii) high net worth entities falling within Article 49(2) of the Order, and (iii) persons at or to whom it can otherwise lawfully be distributed or directed (all such persons together being referred to as “relevant persons”). Any person who is not a relevant person should not act or rely on this announcement or any of its contents.

The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness.

This announcement may include statements that are, or may be deemed to be, “forward‐looking statements”. These forward‐looking statements may be identified by the use of forward‐looking terminology, including the terms “believes”, “estimates”, “plans”, “projects”, “anticipates”, “expects”, “intends”, “may”, “will” or “should” or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Forward‐looking statements may and often do differ materially from actual results. Any forward‐looking statements reflect the Company’s current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to its business, results of operations, financial position, liquidity, prospects, growth or strategies. Forward‐looking statements speak only as of the date they are made.

The Company and its affiliates expressly disclaim any obligation or undertaking to update, review or revise any forward-looking statement contained in this announcement whether as a result of new information, future developments or otherwise.

No reliance may or should be placed by any person for any purposes whatsoever on the information contained in this announcement or on its completeness, accuracy or fairness. The information in this announcement is subject to change.


Additional features:

File: 20261112_FSE_PressRelease_ShareSale _FME_Pricing
File: Fresenius_Headquarters_(c)_Fresenius
File: Fresenius-Flaggen_(c)_Fresenius


12.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Germany
Phone: +49 (0)6172 608-97033
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.com
ISIN: DE000FRE5EN2
WKN: FRE5EN
Indices: DAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Hamburg, Hanover, Stuttgart, Tradegate BSX; Luxembourg Stock Exchange
LEI Code: XDFJ0CYCOO1FXRFTQS51
EQS News ID: 2433360

 
End of News EQS News Service

2433360  12.11.2026 CET/CEST

Strong existing business in the “Branded pharmaceuticals” segment drives positive performance

Dermapharm Holding SE

/ Key word(s): Quarter Results/9 Month figures

Strong existing business in the “Branded pharmaceuticals” segment drives positive performance

12.11.2026 / 07:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


Strong existing business in the “Branded pharmaceuticals” segment drives positive performance

 

  • Consolidated revenue up 1.7% to EUR 884.4 million
  • Strong organic growth in “Branded pharmaceuticals” segment and additional revenue contributions from Mucos and F. Trenka
  • Adjusted EBITDA increases substantially by 5.1% to EUR 248.1 million; adjusted EBITDA margin rises to 28.0% (+0.9 percentage points)
  • Board of Management confirms outlook for 2026, expects consolidated revenue of EUR 1,182–1,218 million and adjusted EBITDA of EUR 331–341 million

 

Grünwald, 12 November 2026 – Dermapharm Holding SE (“Dermapharm”), a rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today publishes its results for the first nine months of 2026.

Consolidated revenue increased by 1.7% year on year to EUR 884.4 million in the first nine months of 2026 (prior-year period: EUR 869.4 million). This growth was driven primarily by the “Branded pharmaceuticals” segment, which saw revenue rise by 8.1%. This is due in particular to strong organic growth in the existing domestic and international business and the additional revenue contributions from the new acquisitions Mucos and F. Trenka. The growth was offset primarily by the planned decline in revenue in the “Parallel import business” segment.

The increase in EBITDA, adjusted for non-recurring items, outpaced revenue growth, rising by 5.1% to EUR 248.1 million (prior-year period: EUR 236.0 million). The adjusted EBITDA margin improved accordingly from 27.1% in the prior-year period to 28.0%. Unadjusted EBITDA amounted to EUR 266.9 million (prior-year period: EUR 230.8 million), corresponding to a margin of 30.2% (prior-year period: 26.5%).

“The performance in the first nine months of 2026 once again underscores the strength and resilience of our business model. The sustained growth of our ‘Branded pharmaceuticals’ segment, driven by our existing business and bolstered by the contributions from our most recent acquisitions, is particularly encouraging. We intend to build on this strong foundation to systematically advance our business in Germany and abroad and unlock further growth opportunities. Looking ahead to the rest of the year, we believe we are well positioned and therefore confirm our guidance for financial year 2026,” said Dr Hans-Georg Feldmeier, CEO of Dermapharm Holding SE.

 

Branded pharmaceuticals
The “Branded pharmaceuticals” segment continued to deliver a positive performance in the first nine months of the year. On top of the additional revenue contributions from Mucos and F. Trenka, this was driven primarily by organic growth in the existing business. Both the core German business and the international business are making significant contributions to growth and earnings. Revenue increased by 8.1% to EUR 486.2 million in the first nine months of 2026 (prior-year figure: EUR 449.8 million).

Adjusted EBITDA rose by 6.7% to EUR 213.0 million (prior-year period: EUR 199.6 million). The adjusted EBITDA margin remains high at 43.8% (prior-year period: 44.4%). Unadjusted EBITDA amounted to EUR 232.7 million (prior-year period: EUR 198.3 million), corresponding to an unadjusted EBITDA margin of 47.9% (prior-year period: 44.1%).

The EUR 19.7 million in non-recurring expenses in this segment were attributable chiefly to adjusted income due to the provisional negative goodwill in connection with the Mucos acquisition.

Other healthcare products
The slight decline in revenue in the “Other healthcare products” segment in the first nine months of 2026 is mainly due to seasonal, regulatory and demand-related factors. The positive performance of individual companies, coupled with favourable currency translation effects and a decrease in cost of materials, partially offset these impacts. Revenue amounted to EUR 261.9 million (prior-year figure: EUR 269.0 million).

Adjusted EBITDA amounted to EUR 41.2 million (prior-year period: EUR 42.1 million). Despite the slight decline in earnings, the adjusted EBITDA margin remains stable at 15.7% (prior-year period: 15.7%). Unadjusted EBITDA increased to EUR 40.3 million (prior-year period: EUR 39.3 million), corresponding to a margin of 15.4% (prior-year period: 14.6%).

The adjusted non-recurring expenses decreased to EUR 0.9 million (prior-year period: EUR 2.8 million) and are attributable primarily to restructuring measures at Arkopharma.

Parallel import business
Revenue declined to EUR 136.3 million in the first nine months of 2026 (prior-year figure: EUR 150.6 million) on account of the portfolio optimisation measures introduced in the previous year.

Lower personnel expenses and other operating expenses could not fully offset the slight decline in the gross profit margin. Adjusted EBITDA therefore amounted to EUR -2.0 million (prior-year figure: EUR ‑1.6 million). Unadjusted EBITDA also amounted to EUR -2.0 million (prior-year period: EUR ‑2.8 million), corresponding to a margin of -1.5% (prior-year period: -1.9%).

While restructuring costs of EUR 1.2 million were normalised in the prior-year period, there were no non-recurring expenses to be normalised in the current reporting period.

Board of Management confirms outlook for 2026 overall
Based on the Company’s performance in the first nine months of financial year 2026, and in light of the expectations for the fourth quarter, the Board of Management confirms that both consolidated revenue and adjusted EBITDA will be in line with the published forecast range of between EUR 1,182–1,218 million and EUR 331–341 million, respectively.

The quarterly statement for Q3 2026 can now be downloaded from https://ir.dermapharm.de/en/.

 

IFRS figures for 9M 2026 and the prior-year period
(excluding segment reconciliation/Group holding company)

EUR million 9M 2026 9M 2025 Change
       
Consolidated revenue 884.4 869.4 1.7%
Branded pharmaceuticals 486.2 449.8 8.1%
Other healthcare products 261.9 269.0 -2.6%
Parallel import business 136.3 150.6 -9.5%
       
Adjusted consolidated EBITDA* 248.1 236.0 5.1%
Branded pharmaceuticals 213.0 199.6 6.7%
Other healthcare products 41.2 42.1 -2.1%
Parallel import business -2.0 -1.6 25.0%
       
Adjusted EBITDA margin (%) 28.0 27.1 0.9 pp
Branded pharmaceuticals 43.8 44.4 -0.6 pp
Other healthcare products 15.7 15.7 0.0 pp
Parallel import business -1.5 -1.1 -0.4 pp
       
Consolidated EBITDA 266.9 230.8 15.6%
Branded pharmaceuticals 232.7 198.3 17.3%
Other healthcare products 40.3 39.3 2.5%
Parallel import business -2.0 -2.8 -28.6%
       
EBITDA margin (%) 30.2 26.5 3.7 pp
Branded pharmaceuticals 47.9 44.1 3.8 pp
Other healthcare products 15.4 14.6 0.8 pp
Parallel import business -1.4 -1.9 0.5 pp

* 9M 2026 EBITDA was adjusted for non-recurring items amounting to EUR -18.8 million.
  9M 2025 EBITDA was adjusted for non-recurring items amounting to EUR 5.2 million.

 

Company profile
Dermapharm – Pharmaceutical Excellence “Made in Europe”

Dermapharm is an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products. Founded in 1991, the Company is based in Grünwald near Munich. In addition to its main location in Brehna near Leipzig, Dermapharm also operates other production, development and distribution locations, including in Germany, the rest of Europe and the United States.

In the “Branded pharmaceuticals” segment, Dermapharm has more than 1,400 marketing authorisations with more than 400 active pharmaceutical ingredients. Dermapharm’s portfolio of pharmaceuticals is tailored to selected therapeutic areas in which the Company is a market leader, especially in Germany. The Company’s integrated business model extends from in-house product development and production through quality management and logistics to the distribution of branded pharmaceuticals by a trained pharmaceutical sales force.

Dermapharm bundles food supplements, herbal pharmaceuticals, cosmetics, medical devices, herbal extracts and medicinal cannabis in its “Other healthcare products” segment. In this segment, Dermapharm can tap the expertise of Arkopharma, the market leader for phytotherapeutic food supplements in France, and the Spanish company Euromed S.A., a leading global manufacturer of herbal extracts and plant-based active ingredients for the pharmaceuticals, nutraceuticals, foodstuffs and cosmetics industries.

Dermapharm also operates the “Parallel import business” segment under the axicorp brand. axicorp imports originator pharmaceuticals from other EU Member States and resells them to pharmaceuticals wholesalers and pharmacies in Germany. This enables axicorp to benefit from the different pricing structures in the individual EU member states. Based on revenue, axicorp is currently the seventh largest parallel importer in Germany.

With a consistent R&D strategy and numerous successful product and company acquisitions and by stepping up its internationalisation efforts, the Group is continuously optimising its business activities and seeks external growth opportunities in addition to organic growth.

 

 

Contact

Investor Relations & Corporate Communications
Britta Hamberger
Tel.: +49 (0)89 64186-233
E-mail: ir@dermapharm.com


12.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Dermapharm Holding SE
Lil-Dagover-Ring 7
82031 Grünwald
Germany
Phone: +49 (0)89 64 86-0
E-mail: ir@dermapharm.com
Internet: ir.dermapharm.de
ISIN: DE000A2GS5D8
WKN: A2GS5D
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
LEI Code: 5299009F0KNZINQQQK37
EQS News ID: 2432720

 
End of News EQS News Service

2432720  12.11.2026 CET/CEST

Continued strong Rx growth: DocMorris raises full-year revenue forecast as part of today’s Capital Markets Day

DocMorris AG / Key word(s): Development of Sales

Continued strong Rx growth: DocMorris raises full-year revenue forecast as part of today’s Capital Markets Day

12-Nov-2026 / 07:00 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


Frauenfeld, 12 November 2026

Press release
Ad hoc announcement pursuant to Art. 53 LR

Continued strong Rx growth: DocMorris raises full-year revenue forecast as part of today’s Capital Markets Day

⋅        Full-year revenue forecast raised to around 15% (previously 12.5 to 15%)
⋅        Continued strong Rx growth in October of over 90%
⋅        TeleClinic expansion into Switzerland with high synergy potential
⋅        Capital Markets Day taking place today in Heerlen/Aachen

Sustained Rx momentum leads to higher full-year forecast
Revenue momentum in the prescription medicines (Rx) business accelerated further in October to over 90 per cent compared to the previous year. DocMorris now expects Rx growth of around 60 per cent for the full year. Against this backdrop, management is raising its forecast for external revenue growth for the full year 2026 to around 15 per cent (previously 12.5 to 15 per cent). The other annual and medium-term targets remain unchanged.

Scaling up Digital Services through the acquisition of Medi24
With the acquisition of Medi24, a leading Swiss telemedicine provider, DocMorris – through its subsidiary TeleClinic – has taken a significant step towards scaling its high-margin Digital Services business outside Germany. Thanks to rapid technology integration and operational synergies, the acquisition will make a substantial contribution to TeleClinic’s EBITDA in its first full year in 2027.

Today’s Capital Markets Day in Heerlen/Aachen
DocMorris is holding its Capital Markets Day today in Heerlen/Aachen. Members of the Executive Board and Management will provide insights into strategic development, operational progress and key value drivers in their respective areas. As part of the programme, participants will also have the opportunity to tour the state-of-the-art logistics centre in Heerlen.

All presentations are available on the website: https://ir-corporate.docmorris.com/en/investor-relations/financial-publications. Video recordings of the presentations will also be made available on the website afterwards.

 

Investors and analyst contact
Kelvin Jörn, Head of Investor Relations
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

19 January 2027 Revenue 2026
18 March 2027 2026 Full-year results and outlook 2027 (hybrid/Zurich, conference call/webcast)
15 April 2027 Q1/2027 Trading Update
12 May 2027 Annual General Meeting, Zurich

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, telemedicine and marketplace with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands. TeleClinic is Germany’s largest telemedicine platform, connecting patients with more than 6,500 doctors. DocMorris operates leading marketplaces for health and personal care products in Southern Europe. With its broad range of products and services, DocMorris is pursuing its vision of becoming the leading digital health companion for everyone to manage their health in one click. Around 1,600 employees in Germany, the Netherlands, Spain, France, Portugal and Switzerland generated an external revenue of CHF 1,186 million serving over 12 million active customers in 2025. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

Disclaimer
This announcement contains certain forward-looking statements about DocMorris AG and its business, either explicitly or implicitly. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results, financial position, performance or achievements of DocMorris AG to differ materially from the future results, performance or achievements expressed or implied by such forward-looking statements. DocMorris AG is making this announcement available as of today’s date and undertakes no obligation to update the forward-looking statements contained herein as a result of new information, future events or for any other reason.

 

 

 


End of Inside Information


Language: English
Company: DocMorris AG
Walzmühlestrasse 49
8500 Frauenfeld
Switzerland
ISIN: CH0042615283
Listed: SIX Swiss Exchange
EQS News ID: 2432746

 
End of Announcement EQS News Service

2432746  12-Nov-2026 CET/CEST

Sandoz launches Ranluspec® (ranibizumab) in Europe, providing an affordable treatment option for patients with retinal diseases

MEDIA RELEASE
 

  • Ranluspec® (ranibizumab) approved by European Commission in February 2026 with equivalent efficacy and comparable safety to reference medicine
  • Launch expands access to vital treatment option for European patients living with various retinal diseases including neovascular (wet) age-related macular degeneration (nAMD)
  • Represents early step towards Sandoz Bio100 ambition, strengthening position in ophthalmology and overall leadership in biosimilars
     

Basel, 12 October 2026 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in affordable medicines, today announces the European launch of Ranluspec® (ranibizumab). Ranluspec was approved by the European Commission in February 2026 and has equivalent efficacy and comparable safety to its reference medicine, Lucentis®*1.

Ranluspec is developed, manufactured and registered by global pharma major Lupin Limited (Lupin) and is being commercialised by Sandoz in the European Union, excluding Germany, under a commercial partnership. It is indicated for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema, proliferative diabetic retinopathy, visual impairment due to macular oedema secondary to retinal vein occlusion and visual impairment due to choroidal neovascularisation2.

Christophe Delenta, President Europe, Sandoz, says: “For patients with these retinal diseases, timely access to effective treatment is critical to preserving vision and helping maintain independence and quality of life. The launch of Ranluspec gives more patients access to a high-quality and affordable version of the medicine they need, while supporting the long-term sustainability of European healthcare systems.”

Around four million people are estimated to have neovascular age-related macular degeneration in France, Germany, Italy, Spain, the UK, the US and Japan3, and between 20% and 35% of people with diabetes in Europe may develop diabetic retinopathy4.

Today’s announcement represents an early step towards the Company’s Bio100 ambition to further strengthen its leadership in biosimilars, targeting more than 100 biosimilars in its portfolio by 2040. The launch also strengthens the Sandoz position in ophthalmology, building on the existing portfolio following the launches of Afqlir® (aflibercept) in Europe and Cimerli® (ranibizumab) in the US.

Sandoz and Lupin announced a commercial partnership in August 2025 for the commercialisation and supply of a ranibizumab biosimilar. Under the terms of the agreement, Sandoz holds exclusive commercialisation rights for Ranluspec across the European Union, excluding Germany, and semi-exclusive rights in France. Sandoz is commercialising Epruvy® (ranibizumab) in Germany under a separate agreement.

*Lucentis® is a registered trademark of Genentech, Inc.
 

About Ranluspec (ranibizumab)
Ranluspec (ranibizumab) is a recombinant humanised IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD), macular oedema following retinal vein occlusion (RVO), diabetic macular oedema (DMO), proliferative diabetic retinopathy (PDR), and choroidal neovascularisation (CNV)2.

DISCLAIMER
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside the control of Sandoz. Should one or more of these risks or uncertainties materialise or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law.

REFERENCES
1 European Medicines Agency (EMA). Lucentis® (ranibizumab): Product information. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/lucentis [Last accessed: November 2026]
2 European Medicines Agency (EMA). Ranluspec® (ranibizumab): Product information. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/ranluspec [Last accessed: November 2026]
3 DRG Clarivate Landscape and Forecast. Dry and Wet Age-Related Macular Degeneration. Report December 2024
4 Eye disease (2024) IDF Europe Site. Available at: https://idf.org/europe/life-with-diabetes/diabetes-related-complications/eye-disease/ [Last accessed: November 2026]

ABOUT SANDOZ
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in affordable medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 colleagues of 100 nationalities work together to ensure over one billion patients are reached by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 medicines addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. In 2026, Sandoz celebrates 20 years of pioneering biosimilars, 80 years of antibiotics manufacturing and 140 years of heritage. In 2025, Sandoz recorded net sales of USD 11.1 billion.  

 

CONTACTS

Global Media Relations contacts

Investor Relations contacts

Global.MediaRelations@sandoz.com

Investor.Relations@sandoz.com

Alexis Kalomparis

+41 792 790285

Craig Marks

+44 7818 942 383

Marina Konrad-Maerk

+41 79 487 7989

Tamara Hackl

+41 79 790 5217

Gregor Rodehueser

+49 170 574 3200

Silvia Siegfried

+41 79 795 9061

EvoNext Holdings SA: EGM invitation and final steps towards combination with Ascend Sport Technology AG

EvoNext Holdings SA / Key word(s): Merger

EvoNext Holdings SA: EGM invitation and final steps towards combination with Ascend Sport Technology AG

12-Nov-2026 / 07:00 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


This press release or the information contained therein is not being issued and may not be distributed in the United States of America, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful or require registration or any other measure and does not constitute an offer of securities for sale in any country

PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
 

EvoNext Holdings SA takes final steps towards combination with Ascend Sport Technology: EGM invitation, proposed Board of Directors and tax rulings

Reinach, Switzerland, 12 November 2026 – EvoNext Holdings SA (SIX: EVE) today published the invitation to its Extraordinary General Meeting (“EGM”) on 3 December 2026 to approve the reverse takeover merger with Ascend Sport Technology AG. EvoNext plans to launch the bookbuilding for a proposed placement of shares on 7 December 2026 at an indicative price range of CHF 2.25 to CHF 2.75 per share (the “Offering”). Additionally, EvoNext has obtained positive feedback on tax rulings from Basel-Land and Lucerne regarding the use of the Company’s tax loss carryforwards. Proposed majority-independent Board of Directors with extensive industry and capital markets expertise

  • EvoNext Holdings SA (SIX: EVE) today published the invitation to the Extraordinary General Meeting on 3 December 2026 to approve the reverse takeover merger with Ascend Sport Technology AG as well as related capital measures
  • EvoNext expects to launch the bookbuilding for the Offering on 7 December 2026 at a proposed price range of CHF 2.25 to CHF 2.75 per share; the Offering, incl. a 10% greenshoe, totals up to CHF 220 million, targets a free float of approximately 40% and comprises predominantly secondary shares and a smaller primary issuance to support future growth initiatives
  • Positive feedback on tax rulings from Basel-Land and Lucerne regarding the use of the Company’s tax loss carryforwards, with the federal ruling pending
  • New, majority-independent Board of Directors proposed for election, bringing in-depth and relevant industry, strategic and capital markets experience
  • Ascend is a Swiss sports technology holding company, bringing together complementary businesses in an ecosystem across the sports technology value chain and forming a leading global platform with AI-enabled monetization capabilities. Ascend serves over 100 rightsholders and more than 500 brands and broadcasters in over 20 countries

EvoNext Holdings SA (SIX: EVE) today published the invitation to an Extraordinary General Meeting and takes the next steps towards a combination with Ascend Sport Technology AG with strong momentum.

Following the announcements of a transaction agreement on 12 October 2026 and of the merger agreement on 2 November 2026, EvoNext and Ascend intend to implement the combination by way of merger by absorption under the Swiss Merger Act, with EvoNext continuing as surviving company (the “Merger”). Subject to the approval of both companies’ general meetings, the Merger will lead to the formation of a listed Swiss sports technology company to operate under the name of Ascend Sport Technology AG and remain listed on SIX Swiss Exchange.

The Offering is conditional upon approval of the Merger and the capital measures by the EGM of EvoNext and by the General Meeting of Ascend, and upon registration of the Merger in the commercial register.

In addition, EvoNext has obtained positive feedback on tax rulings from Basel-Land and Lucerne regarding the use of EvoNext’s tax loss carryforward, with federal ruling still pending. Subject to the applicable conditions, these carryforwards may be available to the combined company and represent an additional element of value for its shareholders.

Offering at a proposed price range of CHF 2.25 to CH 2.75 per share

Following the completion of the ongoing investor pre-marketing, EvoNext plans to publish the offering prospectus and launch the bookbuilding for the Offering on 7 December 2026, at an indicative price range of CHF 2.25 to CHF 2.75 per share.

The offering is expected to consist of 72,000,000 secondary shares (excluding the greenshoe shares), to create an attractive free float and establish a diversified institutional shareholder base, and a smaller primary issuance of 8,000,000 new shares to support future growth initiatives. Including the potential exercise of the greenshoe option of up to 8,000,000 secondary shares, the Offering is expected thus to amount to up to CHF 220 million and result in a free float of approximately 40%.

The final Offering Price is expected to be announced on or around 11 December 2026, Settlement of the Offering is expected to be on 15 December 2026.

The current Ascend shareholders, members of management and members of the Board of Directors of the combined company, as well as certain EvoNext shareholders, will be subject to lock-up arrangements subject to customary exceptions. Fifty percent of the relevant shares will be subject to a 12-month lock-up period following completion of the transaction, with the remaining fifty percent subject to a 24-month lock-up period. Customary orderly market provisions will be in place.

UBS is acting as Sole Global Coordinator and Joint Bookrunner, Zürcher Kantonalbank as Joint Bookrunner, COMMERZBANK (in cooperation with ODDO BHF) as Co-Manager and Octavian as Selling Agent.

Gianluca Ferrari, Chairman of the Board of Directors of EvoNext, said: “Today marks an important milestone for EvoNext shareholders. We look forward to working with Bernard and Daniël Bernard de Roos to make this transaction a success for long-term shareholders. As the founder of Clearway Capital, the largest shareholder of EvoNext, we look forward to being long-term partners to Ascend as it embarks on its journey as a publicly traded company.”

Ascend: the premium platform for the global sports technology market

Ascend is a Swiss sports technology holding company, bringing together complementary businesses across the sports technology value chain and forming a leading global platform with AI-enabled monetization capabilities. Ascend’s businesses serve over 100 rightsholders, including sports leagues, clubs and federations such as FIFA and UEFA, as well as more than 500 brands and broadcasters across over 20 countries and over 500 global advertisers. They are present in over 12 active top leagues worldwide, including the top five European leagues. 19 of Europe’s top 30 clubs count among the clients and to date over 10,000 matches have been supported by Ascend’s technology.

Ascend generated net revenues of ca. CHF 44 million for the Full Year 25/26 and EBITDA of ca. CHF 25 million – resulting in an attractive EBITDA margin of 57%.[1] The Company’s fiscal year starts on 1 July and ends on 30 June.

New Board of Directors

Upon registration of the Merger, the existing Board of Directors of EvoNext will resign and shareholders will elect a new Board of Directors with the majority of the proposed members being independent directors. The following candidates are proposed for election, bringing in-depth and relevant industry, strategic and capital markets experience to the combined company:

Daniël Bernard de Roos, proposed Chair, co-founded Ascend in 2011 and has chaired the board since 2016. He is Chief Growth Officer of the portfolio companies and previously worked at Morgan Stanley. He holds a bachelor’s degree in Business Administration and a master’s degree in Strategy and International Management from the University of St Gallen.

Drs. Bernardus de Roos, proposed member, co-founded Ascend in 2011 and leads the Ascend portfolio companies as CEO. He was previously Managing Director of T.E.A.M. Marketing, where he helped develop the commercial model for the UEFA Champions League. He subsequently worked, e.g., on the acquisition of German Bundesliga broadcast rights at Arena Sport Rechte und Marketing.

André Rüegg, proposed member, has extensive experience in asset management, corporate strategy and the governance of publicly listed companies. He was CEO of Bellevue Group, a Swiss-listed financial services company, after having served as CEO of Bellevue Asset Management. Before joining Bellevue, André spent 14 years at Julius Bär, where he built and led its global asset management distribution business and served on the extended Executive Board.

Abhik Das, proposed member, is a New York-based Partner at Three Hills, a private equity firm. He was previously Head of Private Credit at Golding Capital Partners and worked in investment banking and private markets in London. His experience spans corporate finance, public and private markets investing, and risk management.

Gregor Greber, proposed member, is an experienced Swiss investor and entrepreneur with a strong background in capital markets and strategic investments. He was a founder of zCapital and Veraison Capital and has held various board positions in listed and privately held companies, including Calida Group and R&S Group. He has extensive experience in corporate transformations, capital markets transactions and active ownership. Gregor is currently a board member of Centiel SA and CHELS Ltd.

Michael Frank, proposed member, brings extensive experience in media sales, advertising and commercial development across television, radio, print, online media and both traditional and digital out-of-home advertising. He held various executive roles at Goldbach, including CEO of Goldbach Media and Goldbach Group, and continued to serve on Goldbach Media’s Board since stepping down as Group CEO. Earlier in his career, he was Managing Director of Belcom, where he oversaw Radio 24, TeleZüri and Tele24.

Kathryn Lynn Carter, proposed member, is the former CEO of LA28, the organising committee for the Los Angeles 2028 Olympic and Paralympic Games. She previously served as President of Soccer United Marketing, Major League Soccer’s commercial arm. She has more than 30 years’ experience in sports business, sponsorship and commercial partnerships.

 

Expected timetable

The expected timetable with key steps ahead includes:

  • 3 December 2026 EGM of EvoNext; General Meeting of Ascend
  • 7 December 2026 Publication of prospectus and start of bookbuilding
  • 10 December 2026 End of bookbuilding
  • 11 December 2026 Announcement of the Offering Price; completion of the Merger and the capital measures
  • 14 December 2026 First trading day on SIX Swiss Exchange

Agenda items for the EvoNext EGM on 3 December 2026

The invitation to the Extraordinary General Meeting (EGM) of EvoNext to approve the Merger was published today. The EGM will be held Thursday, 3 December 2026 at 10.00 a.m. CET at the Offices of Pestalozzi Attorneys at Law Ltd, Feldeggstrasse 4, 8008 Zurich, Switzerland.

The Board of Directors of EvoNext Holdings SA proposes as main agenda items regarding:

  • Reverse takeover merger with Ascend Sport Technology AG
    • Approval of the merger agreement
    • Approval of the Merger by absorption, with EvoNext as surviving company
    • Exchange ratio of 1.5611731979 EvoNext shares per Ascend share
  • Capital measures
    • Capital reduction by way of nominal value decrease to CHF 0.006 per share followed by capital increases, i.a. for the issuance of:
      • 199’999’978 merger consideration shares
      • 8’000’000 primary placement shares by way of a cash capital increase
    • Share placement of up to CHF 220 million, comprising a primary and secondary placement with the goal of creating an appropriate free float
  • Further amendments to the Articles of Association in connection with the implementation of the transaction, including a renewal of the resolution on the existing Opting-out
  • Board of Directors
    • Resignation of the existing Board upon registration of the Merger
    • Election of a new Board (see above)
  • Company name and purpose
    • Change company name to Ascend Sport Technology AG and alignment of the Company’s purpose with the future business activities of the combined entity

The Board of Directors of EvoNext is convinced that the Transaction is in the best interests of the Company and its shareholders and provides the basis for long-term operational development and value creation. They unanimously recommend that shareholders approve the Transaction.

The General Meeting of Ascend is also expected to resolve on the approval of the merger agreement and the Merger on 3 December 2026.

The Merger and of the capital measures are expected to be completed on 11 December 2026. EvoNext will inform shareholders and the market of all material developments in due course.

Documentation

The invitation to the Extraordinary General Meeting with the proposed agenda item was published today in the Swiss Official Gazette of Commerce (SOGC). The Invitation is also available here.

[1] 2025/2026 audit not yet completed

Contact EvoNext

investors@evonextholdings.com

Disclaimer

This publication constitutes neither an offer to sell nor a solicitation to buy securities of EvoNext Holdings SA and it does not constitute a prospectus or a similar notice within the meaning of articles 35 et seqq. or 69 of the Swiss Financial Services Act. Any offer and listing of any securities in EvoNext Holdings SA (“Securities”) will be made solely by means of, and on the basis of, a prospectus which is to be published. An investment decision regarding any publicly offered Securities should only be made on the basis of such prospectus. The prospectus will be available free of charge from the accompanying bank.

This publication may contain specific forward-looking statements, e.g., statements including terms like “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of EvoNext Holdings SA or Ascend Sport Technology AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. EvoNext Holdings SA assumes no responsibility to update forward-looking statements or to adapt them to future events or developments. Moreover, financial information contained in this publication may be preliminary and unaudited.

This communication is being distributed only to, and is directed only at (i) persons outside the United Kingdom, (ii) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as “Relevant Persons”). Any potential investment or investment activity to which this communication relates will be available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person who is not a Relevant Person must not act or rely on this communication or any of its contents.

This communication does not constitute an “offer of securities to the public” within the meaning of Regulation 2017/1129 of the European Union (the “Prospectus Regulation”) of the securities referred to in it (the “Securities”) in any member state of the European Economic Area (the “EEA”) or, in the United Kingdom (“UK”), the UK Public Offers and Admissions to Trading Regulations 2024 (the “POATRs”). Any placements of any Securities to persons in the EEA or the UK will be made pursuant to an exemption under the Prospectus Regulation or the POATRs (as applicable), as implemented in member states of the EEA or the UK, from the requirement to produce a prospectus for offers of Securities.

Any securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States or to US persons (as such term is defined in Regulation S under the Securities Act) unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. The issuer of the securities has not registered, and does not intend to register, any portion of any potential placements in the United States, and does not intend to conduct a public offer of securities in the United States.

This communication is not for distribution in the United States, Canada, Australia, Japan or any other jurisdiction into which the same would be unlawful and does not constitute an offer of securities for sale in such countries. This communication does not constitute an offer to sell, or the solicitation of an offer to buy, securities in any jurisdiction in which it is unlawful to do so.

 

 

Additional features:

File: 2026_11_12_EvoNext Ad hoc Release_Invitatiton EGM 2026_+Board


End of Inside Information


Language: English
Company: EvoNext Holdings SA
Angensteinerstrasse 6
4153 Reinach
Switzerland
Phone: +41 61 485 20 00
E-mail: investors@evonextholdings.com
Internet: www.evonextholdings.com
ISIN: CH1262055788
Valor: 126205578
Listed: SIX Swiss Exchange
EQS News ID: 2433300

 
End of Announcement EQS News Service

2433300  12-Nov-2026 CET/CEST

Lonza Appoints Bertha Steinmetz Vilela as Chief Human Resources Officer

  • Bertha Steinmetz Vilela will join Lonza as Chief Human Resources Officer, Executive Vice President and member of the Executive Committee, effective 1 January 2027.
  • Bertha brings extensive international HR leadership experience across pharmaceuticals, biotechnology and manufacturing.
  • Together with the recent additions of Samanta Cimitan, Matt Moorcroft and Hans Trees, this appointment further strengthens executive leadership in support of Lonza’s strategic priorities.

Basel, Switzerland, 12 November 2026 – Lonza, the world’s leading contract development and manufacturing organization (CDMO), announced today the appointment of Bertha Steinmetz Vilela as Chief Human Resources Officer (CHRO), Executive Vice President and member of the Executive Committee. Bertha will join Lonza on 1 January 2027 and succeed Nicoleta Baumgärtner, who has been with the company for more than five years, serving as Chief Human Resources Officer and member of the Executive Committee since 2024, and decided to pursue a new opportunity outside of Lonza.

In this role, Bertha will lead Lonza’s global human resources (HR) function, strengthen organizational effectiveness and leadership capabilities to enable business performance, while continuing to advance the company’s cultural transformation and talent agenda. This latest addition to Lonza’s Executive Committee is part of the wider evolution of Lonza’s senior leadership team, including the recent appointments of Samanta Cimitan as Chief Commercial Officer, Matt Moorcroft as Chief Intelligence & Analytics Officer and Hans Trees as Global Head of Communications, all three as members of the Extended Executive Committee.

Wolfgang Wienand, Chief Executive Officer, Lonza, commented: “I am very pleased to welcome Bertha to Lonza. As we continue to build and drive the transformation of One Lonza, her experience will help us strengthen our high performance culture and further develop the leadership capabilities that will enable our long-term success. Our people are at the heart of our company, and Bertha will play an important role in further advancing an environment where our teams can perform at their best and deliver for our customers and patients. I would also like to sincerely thank Nicoleta for her leadership and the important contributions she has made across two of our businesses and as Chief Human Resources Officer. After more than five years, she has decided to pursue an opportunity outside of Lonza and I wish her every success for the future.”

Bertha currently serves as Head of International Human Resources at Alnylam Pharmaceuticals, where she leads HR across Europe, Canada and Japan. Her experience spans organizational transformation, talent and leadership development, culture, and HR business partnering. She has worked closely with global manufacturing, commercial, and technical operations organizations, and previously held senior roles at Alexion Pharmaceuticals, Novartis and Sandoz. She has a degree in Business Administration from the Pontifical Catholic University of Minas Gerais in Brazil.

Nicoleta joined Lonza in 2021, initially leading HR for the Capsules and Health Ingredients division and later for Biologics. As CHRO, she has helped successfully guide Lonza through significant organizational change and advance its global HR strategy, operating model and agenda. Previously, she held senior roles at Novartis and Roche. She will work closely with Bertha and the HR organization to ensure a smooth transition.

 

Notes to Editors
A high-resolution image of Bertha Steinmetz Vilela is available here. 

STRATEC REPORTS FINAL RESULTS FOR FIRST NINE MONTHS OF 2026

STRATEC SE

/ Key word(s): Quarter Results

STRATEC REPORTS FINAL RESULTS FOR FIRST NINE MONTHS OF 2026

12.11.2026 / 06:55 CET/CEST

The issuer is solely responsible for the content of this announcement.


STRATEC REPORTS FINAL RESULTS FOR FIRST NINE MONTHS OF 2026

  • Adjusted EBIT margin in 9M/2026 increases to 8.3% (9M/2025: 7.3%) based on ongoing high profitability in third quarter (adj. EBIT margin in Q3/2026: 11.3%)
  • Consolidated sales -5.0% at constant currency to € 164.9 million in 9M/2026 (9M/2025: € 175.6 million)
  • Operating cash flow grows to € 39.4 million in 9M/2026 (9M/2025: € -1.4 million)
  • Non-cash measurement effects of € -44.1 million in Q3/2026 in connection with sale of Diatron Group
  • 2026 guidance for continuing operations: stable to slightly higher sales volumes on a constant-currency basis and adjusted EBIT margin of 13.0% to 15.0%

Birkenfeld, November 12, 2026

STRATEC SE, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard) today announced its financial results and major events for the period from January 1, 2026 to September 30, 2026 with the publication of its Quarterly Statement 9M|2026.

KEY FIGURES 1

€ 000s 9M/2026 9M/2025 Change Q3/2026 Q3/2025 Change
Sales 164,907 175,588 -6.1%
(cc: -5.0%)
52,371 56,998 -8.1%
(cc: -8.7%)
Adj. EBITDA 25,304 24,235 +4.4% 9,614 8,165 +17.7%
Adj. EBITDA margin (%) 15.3 13.8 +150 bps 18.4 14.3 +410 bps
Adj. EBIT 13,657 12,824 +6.5% 5,927 4,337 +36.7%
Adj. EBIT margin (%) 8.3 7.3 +100 bps 11.3 7.6 +370 bps
Adj. consolidated net income 7,509 7,104 +5.7% 3,398 2,126 +59.8%
Adj. earnings per share (€) 0.62 0.58 +6.9% 0.28 0.17 +64.7%

Adj. = adjusted / bps = basis points / cc = constant-currency

1  To facilitate comparison, figures have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (including one-off advisory expenses, fees, and reorganization expenses). In addition, negative non-cash measurement effects of € 44.1 million resulting from measures executed in advance of the sale of the Diatron Group (carve-out) were eliminated. The sales agreement was signed in the fourth quarter of 2026.

“The measures we are taking to boost our efficiency and profitability proved effective once again in the third quarter of 2026. In view of this, we managed to significantly increase our profitability in the third quarter even though our sales fell short of expectations. The strong development shown by our operating cash flow at the beginning of the year also continued, offering further confirmation of the effectiveness of the measures we have taken. Sales in the Service Parts division fell short of our expectations, which are based on statistical and historical parameters and account for utilization rates. Here, customers often take measures to optimize their logistics in connection with changing ownership structures. We expect this effect to be merely temporary. The exact timing of any recovery is nevertheless difficult to predict. In parallel, by recently signing the agreement to sell the Diatron Group we are further promoting STRATEC’s ongoing strategic development and focusing on our core business with highly complex analyzer systems for high-end markets. The transaction will open up additional market opportunities for the sold business under the management of its new owner and offers STRATEC potential for future collaboration. Moreover, we expect the transaction to sustainably boost our profitability. This is in particular consistent with our recently updated targets for our continuing operations in the 2026 financial year”, explains Marcus Wolfinger, CEO of STRATEC SE.

BUSINESS PERFORMANCE
The consolidated sales of the STRATEC Group amounted to € 164.9 million in the first nine months of 2026 compared with € 175.6 million in the previous year’s period. This corresponds to a reduction of 5.0% on a constant-currency basis and of 6.1% in nominal terms. The subdued sales performance is due in particular to lower sales in the Service Parts and Consumables businesses. This was due to the prolongation into the third quarter of 2026 of measures taken by customers with amended ownership structures. These are clearly intended to enhance capital efficiency and achieve targeted optimizations in service costs and associated inventory holdings. Due to billing factors and a high basis for comparison, sales with Development and Services also decreased. By contrast, Systems sales showed a slight increase in the first nine months of 2026. This was due in particular to higher call-up volumes for immunodiagnostics and molecular diagnostics systems. Conversely, hematology system sales at the Diatron subsidiary showed a marked reduction.

Adjusted EBIT increased to € 13.7 million in the first nine months of 2026, up from € 12.8 million in the previous year’s period. Due in particular to a higher gross margin, the adjusted EBIT margin therefore rose year-on-year by 100 basis points to 8.3% (9M/2025: 7.3%). This improvement resulted above all from measures to cut personnel expenses, overall cost discipline, product mix effects, and currency translation effects.

Adjusted consolidated net income for the first nine months of 2026 stood at € 7.5 million, as against € 7.1 million in the previous year’s period. Adjusted earnings per share amounted to € 0.62 (9M/2025: € 0.58).

The positive performance shown by the cash flow from operating activities in the first half continued in the third quarter of 2026. Overall, well-focused working capital management and reductions in receivables after the strong year-end business in 2025 led the cash flow from operating activities to increase significantly from € -1.4 million in the previous year’s period to € 39.4 million in the first nine months 2026.

The key earnings figures for the first nine months of 2026 have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (including one-off advisory expenses, fees, and reorganization expenses). In addition, negative non-cash measurement effects of € 44.1 million resulting from measures executed in advance of the sale of the Diatron Group (carve-out) were eliminated. The sales agreement with a consortium of Indian investors was signed in the fourth quarter of 2026. A reconciliation of the adjusted figures with those reported in the consolidated statement of comprehensive income can be found in the Quarterly Statement 9M|2026 also published today.

2026 FINANCIAL GUIDANCE
On October 30, 2026, STRATEC announced that it had signed an agreement for the sale of the Diatron Group. The sales and earnings from the sold business, as well as the impairments arising in connection with the transactions and the deconsolidation effect expected for the fourth quarter of 2026 (expected between € 4.0 million and € 9.0 million), will be retrospectively allocated to discontinued operations for the 2026 financial year. The following guidance provided for the 2026 financial year therefore refers to continuing operations. Based on pro-forma sales (adjusted to exclude the sold business) of € 223.5 million for the 2025 financial year, STRATEC expects to report stable to slightly higher sales on a constant-currency basis in the 2026 financial year. Following separation of the sold business, STRATEC is forecasting an adjusted EBIT margin of between 13.0% and 15.0% for the 2026 financial year.

Based on updated planning, STRATEC expects its total investments in property, plant and equipment and in intangible assets in continuing operations to correspond to 5.0% to 7.0% of sales in the 2026 financial year.

PROJECTS AND OTHER DEVELOPMENTS
In collaboration with its partners, STRATEC made scheduled advances with numerous projects once again in the third quarter of 2026. One major focus involved transferring newly developed systems to serial production. This also applies for the first time to the US location, which to date primarily specialized in consumables production. With these preparations to start the first serial production of systems, STRATEC is strengthening its US market presence and taking targeted steps to extend its local footprint beyond consumables to include instruments as well.

In addition, STRATEC platforms in the areas of immunodiagnostics and molecular diagnostics have reached advanced stages of evaluation at several potential customers. The high volume of demand for solutions aimed at significantly extending the lifecycles of products already established in the market, a trend already apparent for several quarters now, continued in the third quarter of 2026. Key drivers of this development include current changes in the regulatory environment, such as increasingly strict cybersecurity requirements on the part of the FDA and amended environmental requirements for material conformity.

STRATEC expects these developments to promote consolidation within the sector in the longer term. Thanks to its comprehensive experience in lifecycle management, its regulatory expertise, and its broad-based portfolio of cybersecurity services, STRATEC is strongly positioned to actively accompany these market changes and seize the resultant opportunities.

DEVELOPMENT IN PERSONNEL
Including personnel hired from employment agencies and trainees, the STRATEC Group had a total of 1,352 employees as of September 30, 2026 (previous year: 1,420 employees), corresponding to a reduction of 4.8% compared with the previous year’s reporting date.

QUARTERLY STATEMENT 9M|2026
The Quarterly Statement 9M|2026 of STRATEC SE has been published on the company’s website at www.stratec.com/financial_reports.

CONFERENCE CALL AND AUDIO WEBCAST
To mark the publication of the final results for the first nine months of 2026, STRATEC will hold a conference call in English at 3:00 p.m. (CET) today, Thursday, November 12, 2026.

You will receive the dial-in data (telephone number, password + individual PIN) following brief registration at the following link: www.stratec.com/registration

The conference call will also be available at the same time as an audio webcast at http://www.stratec.com/audiowebcast20261112 (brief registration required). Please note that no questions can be submitted via the audio webcast. Clicking this link also enables you to follow or download the slide presentation.

ABOUT STRATEC
STRATEC SE (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and life sciences. Furthermore, the company offers complex consumables for diagnostic and medical applications. For its analyzer systems and consumables, STRATEC covers the entire value chain – from development to design and production through to quality assurance.

The partners market the systems, software, and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange.

FURTHER INFORMATION IS AVAILABLE FROM:
STRATEC SE
Jan Keppeler, CFA | Investor Relations, Sustainability & Corporate Communications
Tel: +49 7082 7916-6515
ir@stratec.com
www.stratec.com


12.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: STRATEC SE
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec.com
Internet: www.stratec.com
ISIN: DE000STRA555
WKN: STRA55
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
LEI Code: 529900ZZJWANAFSPGV30
EQS News ID: 2433130

 
End of News EQS News Service

2433130  12.11.2026 CET/CEST

Fresenius announces intention to sell approximately 13.4 million shares in Fresenius Medical Care AG, reducing its financial investment to approximately 20 per cent

Fresenius SE & Co. KGaA

/ Key word(s): Miscellaneous

Fresenius announces intention to sell approximately 13.4 million shares in Fresenius Medical Care AG, reducing its financial investment to approximately 20 per cent (news with additional features)

11.11.2026 / 18:14 CET/CEST

The issuer is solely responsible for the content of this announcement.


THIS ANNOUNCEMENT, INCLUDING THE INFORMATION INCLUDED HEREIN, IS RESTRICTED AND IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES OF THE SECURITIES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

Steffi Kim
Group Communications

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 175 3284722
steffi.kim@fresenius.com
www.fresenius.com
 

  • Fresenius intends to sell approximately 13.4 million shares in Fresenius Medical Care AG, equivalent to approximately 5 per cent of Fresenius Medical Care’s issued share capital, via an accelerated bookbuild offering to institutional investors
  • On completion, Fresenius’s financial investment in Fresenius Medical Care will reduce from approximately 25 per cent1 to approximately 20 per cent1
  • The sale continues Fresenius’s disciplined, value-oriented reduction of the financial investment; proceeds will be used consistently with the stated capital allocation priorities set out under #FutureFresenius
 

Fresenius SE & Co. KGaA (XETR: FRE; OTCM: FSNUY) today announced its intention to sell approximately 13.4 million shares in Fresenius Medical Care AG (XETR: FME; NYSE: FMS) through a placing to institutional investors by way of an accelerated bookbuild offering. The placing price will be determined on completion of the bookbuild, and the result will be announced thereafter. The sale would reduce Fresenius’s financial investment in Fresenius Medical Care from approximately 25 per cent1 to approximately 20 per cent1 of issued share capital.

“With the structured reduction of our stake in Fresenius Medical Care we are creating further capacity to redeploy that capital into our growth platforms. That was the purpose of #FutureFresenius, and it is the foundation REJUVENATE builds on – a more focused Fresenius, with a stronger balance sheet and the strategic flexibility to act on the opportunities in front of us,” said Michael Sen, CEO of Fresenius.

The net proceeds will be applied consistent with the stated capital allocation priorities set out under #FutureFresenius.

Since the deconsolidation of Fresenius Medical Care on 30 November 2023, Fresenius has managed its holding as a financial investment and has progressively reduced it, including through participation on a pro-rata basis in Fresenius Medical Care’s share buyback program as well as a sale of 7.8 million shares in August this year. Today’s placing is a further step in that reduction, supporting Fresenius’ commitment to delivering long-term profitable growth and creating shareholder value.

●●●
Transaction Details

  • BNP Paribas, BofA Securities Europe SA, Deutsche Bank Aktiengesellschaft and J.P. Morgan SE are acting as Joint Bookrunners for the placing.
  • The bookbuild will commence immediately following this announcement; pricing and allocation are expected to be announced before the opening of Xetra trading on 12 November 2026.
  • Fresenius has agreed a lock-up on its remaining Fresenius Medical Care shares of 90 days, subject to customary exceptions.

 

●●●

Footnotes
1Prior to any future exchange of bonds into Fresenius Medical Care shares and prior to any share cancellation under the current Fresenius Medical Care share buyback program 
 

Fresenius (XFRA: FRE, OTC: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, medical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450 million people each year. Fresenius Helios is Europe’s largest private hospital operator, treating around 27 million patients annually.

With more than 178,000 employees and operating in more than 60 countries, Fresenius generated €22.6 billion in revenue in 2025.

For more information, visit www.fresenius.com and follow Fresenius on LinkedIn.

Fresenius Medical Care AG is an independent, separately listed company (XETR: FME; NYSE: FMS), in which Fresenius SE & Co. KGaA holds a financial investment of approximately 25 per cent1; Fresenius Medical Care’s results are not consolidated in the Fresenius Group’s revenue and earnings.

Forward-Looking Statements
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Correspondence Address
 

Fresenius SE & Co. KGaA
 
Fresenius Management SE
Registered Office
Bad Homburg, Germany
 
Registered Office
Bad Homburg, Germany
 
Commercial Register
Amtsgericht Bad Homburg, HRB 11852
 
Commercial Register
Amtsgericht Bad Homburg, HRB 11673
 
Chairman of the Supervisory Board
Wolfgang Kirsch
Management Board
Michael Sen (Chairman), Sara Hennicken, Dr. Marc-Alexander Mahl,  Dr. Michael Moser, Dr. Christian Pawlu 

Chairman of the Supervisory Board
Wolfgang Kirsch

Securities Information
Fresenius SE & Co. KGaA is listed on the Frankfurt Stock Exchange and is a member of the DAX 40 index. The shares are traded on Xetra, the electronic trading venue of Deutsche Börse, under the ticker FRE.
ISIN: DE000FRE5EN2 ● WKN: FRE5EN

American Depository Receipts
Fresenius SE & Co. KGaA maintains a sponsored Level I American Depositary Receipt programme, traded over the counter in the United States on the OTC Markets platform under the ticker FSNUY, at a ratio of four American Depositary Receipts to one ordinary share. Depositary bank: J.P. Morgan Chase Bank N.A.
ISIN: US35804M1053 ● CUSIP: 35804M105

Contacts
For Media contacts, click here, and to contact Investor Relations, click here.

IMPORTANT NOTICE

This announcement is not a prospectus and does not contain or constitute an offer of securities for sale in or into any jurisdiction, including the United States, Canada, Australia, Japan, South Africa or any jurisdiction in which offers or sales of the securities would be prohibited by applicable law. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction.

This announcement is not an offer to sell, or solicitation of an offer to buy, any securities in the United States. The securities described herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will be no public offering of the securities described herein in the United States or anywhere else.

In member states of the European Economic Area (“EEA”) and the United Kingdom, this announcement is directed exclusively at persons who are “qualified investors” within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (“Prospectus Regulation”) or the Public Offers and Admissions to Trading Regulations 2024 (“POATRs”) (“Qualified Investors”).

In addition, in the UK, this announcement is only being distributed to and is only directed at (i) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), (ii) high net worth entities falling within Article 49(2) of the Order, and (iii) persons at or to whom it can otherwise lawfully be distributed or directed (all such persons together being referred to as “relevant persons”). Any person who is not a relevant person should not act or rely on this announcement or any of its contents.

The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness.

This announcement may include statements that are, or may be deemed to be, “forward‐looking statements”. These forward‐looking statements may be identified by the use of forward‐looking terminology, including the terms “believes”, “estimates”, “plans”, “projects”, “anticipates”, “expects”, “intends”, “may”, “will” or “should” or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Forward‐looking statements may and often do differ materially from actual results. Any forward‐looking statements reflect the Company’s current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to its business, results of operations, financial position, liquidity, prospects, growth or strategies. Forward‐looking statements speak only as of the date they are made.

The Company and its affiliates expressly disclaim any obligation or undertaking to update, review or revise any forward-looking statement contained in this announcement whether as a result of new information, future developments or otherwise.

No reliance may or should be placed by any person for any purposes whatsoever on the information contained in this announcement or on its completeness, accuracy or fairness. The information in this announcement is subject to change.

– End –
 


Additional features:

File: 20261111_FSE_PressRelease_ShareSale _FME_Launch


11.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Germany
Phone: +49 (0)6172 608-97033
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.com
ISIN: DE000FRE5EN2
WKN: FRE5EN
Indices: DAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Hamburg, Hanover, Stuttgart, Tradegate BSX; Luxembourg Stock Exchange
LEI Code: XDFJ0CYCOO1FXRFTQS51
EQS News ID: 2433194

 
End of News EQS News Service

2433194  11.11.2026 CET/CEST